Donating Online
Remember it's easier than ever to register your fundraising event online, or to make a donation to someone you know that is registered and raising money for the Fund.

Here’s how:
Just Giving – simply log on to www.justgiving.com
CAF (Charities Aid Foundation) – simply log on to www.cafonline.org

Donations can be made securely online, which makes this a great way of collecting sponsorship money for your fundraising events. So if you know someone who would like to register his or her event please pass on this information – thank you.

Donating and Fundraising

You could help us by:
- Adopting the Fund as your “Charity of the Year” if you are a business or corporate donor
- Making a Gift Aid or tax efficient donation
- Setting up a monthly direct debit or standing order donation
- Organising your own fundraising event
- Registering your fundraising event on Just Giving www.justgiving.com or CAF www.cafonline.org
- Making an endowment or leaving the Fund a legacy

Sponsorship forms can now be downloaded from www.justgiving.com or CAF www.cafonline.org

The Fund welcomes all donations large and small to support its work in memory of June Hancock.

www.junehancockfund.org

Our aims
Encourage and sponsor vital epidemiological research into the causes of mesothelioma
Contribute to clinical trials with novel drug therapies for mesothelioma
Raise awareness of the disease amongst healthcare professionals and the public at large
Provide good quality up to date information and advice for mesothelioma sufferers and their carers
Campaign for delivery of the Mesothelioma Charter

Contact Us
If you would like to get in touch, here’s how:

Write to us or send donations to:
The June Hancock Mesothelioma Research Fund
Riverside East
2 Millands
Sheffield
S3 8DT

Please make cheques or postal orders payable to “The June Hancock Mesothelioma Research Fund”.

Alternatively, visit our website:
www.junehancockfund.org

By telephone:
0114 274 4420

In the last 11 years, the Fund has raised more than £700,000 of which over 95% has been spent on research into the disease and potential treatments

Fund backs cancer vaccine for mesothelioma trial
JHMRF-funded research into using the body’s own immune system to fight mesothelioma is now proceeding to a clinical trial.

Fund trustees said they were delighted that the laboratory work carried out by Dr Zsuzsanna Tabi’s team of cancer immunologists at Cardiff University was moving into an exciting new phase with trials of an experimental cancer vaccine.

Dr Tabi has established a partnership with Dr Jason Lester, an oncologist at Velindre Cancer Centre in Cardiff, and UK biotech company, Oxford BioMedica to study the effects of the experimental cancer vaccine TroVax® in mesothelioma.

A feasibility study funded by the JHMRF will begin in the autumn using TroVax® in combination with first-line chemotherapy agents Alimta and Cisplatin.

JHMRF trustee Dr Kate Hill said: “The Cardiff immunology team is well established in their field and has shown a tremendous commitment to working with us to pursue research in mesothelioma, and we are delighted to continue our association with Dr Tabi and her colleagues.

“There are never guarantees in any type of experimental research but we believe that immunotherapy has potential in the treatment of mesothelioma.

Oxford BioMedica Chief Scientific Officer Stuart Naylor said: “The pioneering work undertaken by Dr Tabi and her colleagues has identified ST4 as an exciting new therapeutic target in mesothelioma, a disease which has few treatment options available to patients.

“Oxford BioMedica is happy to be able to supply TroVax® for this phase I/II clinical study in mesothelioma patients and we are very pleased to be able to work with the June Hancock fund and colleagues at the Velindre hospitl.”

Therapeutic cancer vaccines can be used in a number of ways. They can be injected into patients to stimulate the body’s own defence system to produce immune cells and antibodies which will attack the cancer cells by targeting specific markers (antigens) on them.

Immunotherapy may offer new ways of attacking cancer cells by targeting the unique markers on cancer cells, and by using the patients’ own immune cells and clotting them in the laboratory to fight cancer cells more effectively, before injecting them back into the patient.

TroVax® is a cancer vaccine which targets ST4, a protein expressed on most common tumour types and which has recently been shown to be present on mesothelioma cells. Dr Tabi and her colleagues. TroVax® has been shown to be safe and effective at inducing immune responses in other types of cancer but this study will be the first time that it will be used in mesothelioma in the UK.

The Fund is constantly seeking to advance the range and type of treatments on offer to patients by supporting high quality research and exploring novel approaches to therapy.

US biotech company Dendreon recently became the first to have a cancer vaccine approved by the US drug licensing agency but more research is needed to make immunotherapy part of standard-of-care in cancer treatment.
and founders please visit our

We continue June's battle in her projects. 

Dr Salty Al-Taei is working on a JHMRF-funded project on ways of stimulating patients’ immune systems into recognising and killing mesothelioma.

The Fund has enabled her to present a poster at a major conference in Keystone, Colorado earlier this year on the cellular and molecular biology of immune escape in cancer.

Dr Al-Taei said: “My poster on tumour-associated suppressor cells in malignant pleural mesothelioma attracted a lot of mixed interest from delegates. “Some were intrigued by our data on the immunological profile of the cancer and the pleural fluid environment and encouraged by the development of immunotherapies for mesothelioma. “It’s also fair to report that there was scepticism, that this aggressive disease is beyond any medical intervention and funding for future research will be difficult due to the life expectancy and occurrence rate of mesothelioma. “Unfortunately, we are all too aware that mesothelioma research will always struggle to compete with the more common and well publicised cancers such as breast and prostate and it certainly had negligently contaminated factory in Armley, Leeds. They had negligently contaminated their own workforce and the local neighbourhood with deadly asbestos dust. This was described as a true “David and Goliath” battle and against all the odds June won her case and proved that T&M were negligent. June was 61 years old and her Mum 67 years old when they lost their lives to mesothelioma – exposed as a young innocent family living in the shadow of the factory.

The founders of the June Hancock Fund pledged to continue raising awareness of the disease, providing up to date quality information and advice, and to finance independently reviewed specific mesothelioma research projects.

We continue June’s battle in her name.

For a full list of our trustees and founders please visit our website: www.junehancockfund.org

Colorado showcase for Fund immunologist

Dr Saly Al-Taei is working on a JHMRF-funded project on ways of stimulating patients’ immune systems into recognising and killing mesothelioma.

The Fund enabled her to present a poster at a major conference in Keystone, Colorado earlier this year on the cellular and molecular biology of immune escape in cancer.

Dr Al-Taei said: “My poster on tumour-associated suppressor cells in malignant pleural mesothelioma attracted a lot of mixed interest from delegates. “Some were intrigued by our data on the immunological profile of the cancer and the pleural fluid environment and encouraged by the development of immunotherapies for mesothelioma. “It’s also fair to report that there was scepticism, that this aggressive disease is beyond any medical intervention and funding for future research will be difficult due to the life expectancy and occurrence rate of mesothelioma. “Unfortunately, we are all too aware that mesothelioma research will always struggle to compete with the more common and well publicised cancers such as breast and prostate and it certainly had negligently contaminated factory in Armley, Leeds. They had negligently contaminated their own workforce and the local neighbourhood with deadly asbestos dust. This was described as a true “David and Goliath” battle and against all the odds June won her case and proved that T&M were negligent. June was 61 years old and her Mum 67 years old when they lost their lives to mesothelioma – exposed as a young innocent family living in the shadow of the factory.

The founders of the June Hancock Fund pledged to continue raising awareness of the disease, providing up to date quality information and advice, and to finance independently reviewed specific mesothelioma research projects.

We continue June’s battle in her name.

For a full list of our trustees and founders please visit our website: www.juneh Hancockfund.org

A record breaking year

I am very proud of my sports club, Reading Roadrunners. My team mates had a good year at marathons, half-marathons, 10K’s and the like, but they also found time to collect a cool £43K plus for the June Hancock Mesothelioma Research Fund (JHMRF).

The Club picks a different charity each year at its February AGM. Autism, epilepsy, cancer and strokes, you name it, we have probably collected for it at one point.

Last year I persuaded the Club to adopt the JHMRF – not that they needed much persuading, because as soon as I broke the news that I myself have mesothelioma, they rallied round. Not only have they given me support through what has been a hard year health-wise, but they also pulled out all the stops to achieve a fundraising record – the most the Club has ever raised in a single year.

This was even more gratifying as in the course of the year, on my watch as charity-coordinator, the tragic milestone of 400K in 20 years of fundraising was passed.

I was deeply honoured when as many as five JHMRF Trustees attended our dinner dance this February (2010); at which traditionally the ceremonial handover of the cheque to the outgoing charity takes place.

Mind you, I barely made it myself, as it came at the tail end of four lots of chemotherapy over the Christmas period. I was too weak to dance and thin as a rake – down to 60 kilos from my usual 72.

Nevertheless I managed to make a speech summing up the year and as was rewarded by Trustee Vanessa Bridge’s announcement that a “Sally Lee Mesothelioma Research Fellowship” was being set up!

Since then I have mercifully put on weight and generally improved to an amazing degree. A few months back I thought I was a goner – whereas now I am back jogging again, albeit slowly.

I am convinced that my 25 years of distance running has helped me fight this dreadful disease – indeed, I did two half marathons even after diagnosis, together with my wife, who has done so much to nurse me back to a degree of fitness.

So how did we collect all that dough? Individual sponsorships raised in a good few thousand. Besides my own effort (running 13 miles effectively on one leg), one colleague ran the London marathon (aka the Dardanelles), in the footsteps – or rather the wake – of Lord Byron! Another colleague tackled Mount Snowdon, despite recovering from a motorbike accident.

Car boot sales organised by the Club accounted for another £8,000 plus. (Besides having our own stall, the local council allows us to profit from the cars’ entry money)

Bucket collections, raffles, refreshments at events – and even a spot of bucketing – make up the rest, on the basis that every little counts!

In other words, we never let slip an opportunity to raise a bob or two!

Even after the accounting period was officially closed, monies have continued to trickle in. One of our girls recently organised her second mini indoor Triathlon at a local gym, raising some £350 in entry fees. This will be matched by Microsoft, the company she works for.

Also, some extra cash is expected to be generated from sales of the Red Hot Bagels CD and Kathy Tyfor’s intriguing book of Running Versus.

The Bagels fall under the “world music” category – or more specifically Klezmer – an East European Jewish style. Their new album Big Bang costs £10, of which they will give £8 specifically Klezmer – an East European Jewish style. Their new album Big Bang costs £10, of which they will give £8,000 plus. (Besides having our own stall, the local council allows us to profit from the cars’ entry money).

Kathy Tytler’s book – “Achieving some sort of Work Life Balance” – is available to go to the JHMRF. To find out more visit www.junehancockfund.org/Kathy-Tytler or contact Kathy at kathy_f@fsmail.net

So let us all continue to give the JHMRF fund all the support it deserves in the coming years!